Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QLF 31907

Next Previous
X
Search
Drug Profile

QLF 31907

Alternative Names: QLF-31907

Latest Information Update: 09 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma; Urogenital cancer

Most Recent Events

  • 31 May 2024 Efficacy and safety data from the Phase Ia trial in Cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology 2024 (ASCO-2024)
  • 01 May 2024 Qilu Pharmaceutical plans a phase I/II trial for Solid tumours (Late-stage disease, Combination therapy) in unknown location (IV) (NCT06394713)
  • 26 Apr 2023 Qilu Pharmaceuticals plans a phase II trial for Malignant melanoma and Urogenital cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in China (NCT05823246)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top